Market Domination hosts Julie Hyman and Josh Lipton report on the analyst note, also noting Novo Nordisk's (NVO) and Roche's (ROG.SW, RHHBY) own plans for experimental obesity pills. In an August ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

Overall, recent studies have shown that GLP-1 drugs have led to a 10-20% reduction in body weight and lowered the risk of heart attack, stroke and cardiovascular death by approximately 20%.

Infusions of Vertex and CRISPR Therapeutics’ Casgevy and bluebird bio’s Lyfgenia have begun; Moderna targets 10 approvals ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...

Roche presented early-stage data on its obesity injection and pill at EASD. Meanwhile, Oura enters into metabolic health market with acquisition of Veri.

The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders ...

Jared Holz thought about taking one of the new GLP-1 drugs for weight loss for months before he actually filled the prescription. And even when he got the drug, he waited a month before using it.

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...

Roche is sharpening its focus on obesity treatments following the $2.7 billion acquisition of Carmot Therapeutics, adding ...

As Eli Lilly and Novo Nordisk continue to dominate the lucrative weight-loss drug market, smaller competitors are gearing up ...

Roughly three-quarters of people who took both an injectable and pill version of a new GLP-1 weight loss drug in trials ...